Although the evidence for CP therapy remains inconclusive, preliminary trials for CP suggest that there may be some benefits, and there is growing consensus that CP is an important first-line immunotherapy for emerging viral infections when other specific treatments are not available [58]. The gene discussed is CP; the disease is viral infectious disease.